Loading stock data…
$2.77+0.02 (+0.55%)
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
Protalix BioTherapeutics, Inc. in the Healthcare sector is trading at $2.77 with a market capitalization of $214M. Wall Street consensus targets $11.00 (2 analysts), implying a +297.8% move over the next 12 months. The stock is currently 13% below its 52-week high of $3.19, remaining 16.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $19.90M↓ | $33.75M↑ | $9.12M↓ | $17.85M↑ | $15.66M |
| Gross Profit | $12.13M↓ | $29.62M↑ | $4.50M↓ | $9.53M↓ | $9.79M |
| Operating Income | $4.67M↓ | $21.15M↑ | -$4.66M↓ | $2.13M↑ | $1.17M |
| Net Income | $3.78M↓ | $18.32M↑ | -$5.50M↓ | $2.35M↑ | $164,000 |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Ele...